FDA OKs Novo’s Fiasp for diabetic children

The FDA approves Novo Nordisk’s (NVO -0.2%) Fiasp (insulin aspart) 100 U/mL as a mealtime insulin option for children with type 1 diabetes (T1D).

The FDA approved the fast-acting prandial insulin in adults with T1D or T2D in September 2017 followed by approval to use it in insulin pumps for this population in October 2019.

https://seekingalpha.com/news/3529789-fda-oks-novos-fiasp-for-diabetic-children